RhoA triggers a specific signaling pathway that generates transforming microvesicles in cancer cells

Oncogene

Volumn 31, Issue 45, 2012, Pages 4740-4749

  Li, B ^a   Antonyak, M A ^a   Zhang, J ^a   Cerione, R A ^a  

^a Department of Obstetrics Gynecology   (United States)

Author keywords

LIMK; Microvesicles; Oncosomes; RhoA; ROCK; Tissue transglutaminase

Indexed keywords

MITOMYCIN C; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOGENESIS; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CARCINOGENESIS; CELL STRAIN 3T3; CELL TRANSFORMATION; CELL VACUOLE; CIRCULATION; CONTROLLED STUDY; DONOR; FEMALE; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MICROVESICLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ACTIN DEPOLYMERIZING FACTORS; ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CELL-DERIVED MICROPARTICLES; ENZYME ACTIVATION; HUMANS; LIM KINASES; MICE; NEOPLASMS; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION;

MUS;

EID: 84869097694     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.636     Document Type: Article

References (35)

1. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 2008; 10: 619-624. (Pubitemid 351627382)
2. Al-Nedawi K, Meehan B, Rak J. Microvesicles: messengers and mediators of tumor progression. Cell Cycle 2009; 8: 2014-2018.
3. Antonyak MA, Li B, Boroughs LK, Johnson JL, Druso JE, Bryant KL et al. Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells. Proc Natl Acad Sci USA 2011; 108: 4852-4857.
4. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008; 10: 1470-1476.
5. Lee TH, D'Asti E, Magnus N, Al-Nedawi K, Meehan B, Rak J. Microvesicles as mediators of intercellular communication in cancer-the emerging science of cellular 'debris'. Semin Immunopathol 2011; 33: 455-467.
6. Rak J. Microparticles in cancer. Semin. Thromb Hemost 2010; 36: 888-906.
7. Keller S, Sanderson MP, Stoeck A, Altevogt P. Exosomes: from biogenesis and secretion to biological function. Immunol Lett 2006; 107: 102-108. (Pubitemid 44779821)
8. Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: artefacts no more. Trends Cell Biol 2009; 19: 43-51.
9. Hao S, Ye Z, Li F, Meng Q, Qureshi M, Yang J et al. Epigenetic transfer of metastatic activity by uptake of highly metastatic B16 melanoma cell-released exosomes. Exp Oncol 2006; 28: 126-131. (Pubitemid 44140264)
10. Catellana D, Zobairi F, Martinez, MC, Panaro MA, Mitolo V, Freyssinet JM et al. Membrane microvesicles as actors in the establishment of a favorable prostatic tumoral niche: a role for activated fibroblasts and CX3CL1-CX3CR1 axis. Cancer Res 2009; 69: 785-793.
11. Jung T, Castellana D, Klingbeil P, Cuesta Hernandez I, Vitacolonna M, Orlicky DJ et al. CD44v6 dependence of premetastatic niche preparation by exosomes. Neoplasia 2009; 11: 1093-1105.
12. Narumiya S, Tanji M, Ishizaki T. Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev 2009; 28: 65-76.
13. Li B, Antonyak MA, Druso JE, Cheng L, Nikitin AY, Cerione RA. EGF potentiated oncogenesis requires a tissue transglutaminase-dependent signaling pathway leading to Src activation. Proc Natl Acad Sci USA 2010; 107: 1408-1413.
14. Yuan L, Siegel M, Choi K, Khosla C, Miller CR, Jackson EN et al. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene 2007; 26: 2563-2573. (Pubitemid 46632005)
15. Teis D, Saksena S, Emr SD. SnapShot: The ESCRT machinery. Cell 2009; 137: 182.
16. Heasman SJ, Ridley AJ. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol 2008; 9: 690-701.
17. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26: 3291-3310. (Pubitemid 46763022)
18. Muralidharan-Chari V, Clancy J, Plou C, Romao M, Chavrier P, Raposo G et al. ARF6-regulated shedding of tumor cell-derived plasma membrane microvesicles. Curr Biol 2009; 19: 1875-1885.
19. Narumiya S, Ishizaki T, Uehata M. Use and properties of ROCK-specific inhibitor Y-27632. Methods Enzymol 2000; 325: 273-284.
20. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006; 98: 322-334.
21. Kawano Y, Fukata Y, Oshiro N, Amano M, Nakamura T, Ito M et al. Phosphorylation of myosin-binding subunit (MBS) of myosin phosphatase by Rho-kinase in vivo. J Cell Biol 1999; 147: 1023-1038.
22. Maekawa M, Ishizaki T, Boku S, Watanabe N, Fujita A, Iwamatsu A et al. Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science 1999; 285: 895-898. (Pubitemid 29381991)
23. Yang N, Higuchi O, Ohashi K, Nagata K, Wada A, Kangawa K et al. Cofilin phosphorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization. Nature 1998; 393: 809-812. (Pubitemid 28299495)
24. Petrache I, Birukov K, Zaiman AL, Crow MT, Deng H, Wadgaonkar R et al. Caspasedependent cleavage of myosin light chain kinase (MLCK) is involved in TNFalpha-mediated bovine pulmonary endothelial cell apoptosis. FASEB J 2003; 17: 407-416. (Pubitemid 36292956)
25. Mbeunkui F, Johann Jr DJ. Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol 2009; 63: 571-582.
26. Davila M, Frost AR, Grizzle WE, Chakrabarti R. LIM kinase 1 is essential for the invasive growth of prostate epithelial cells: implications in prostate cancer. J Biol Chem 2003; 278: 36868-36875. (Pubitemid 37140021)
27. Davila M, Jhala D, Ghosh D, Grizzle WE, Chakrabarti R. Expression of LIM kinase 1 is associated with reversible G1/S phase arrest, chromosomal instability and prostate cancer. Mol Cancer 2007; 6: 40.
28. Yoshioka K, Foletta V, Bernard O, Itoh K. A role for LIM kinase in cancer invasion. Proc Natl Acad Sci USA 2003; 100: 7247-7252. (Pubitemid 36706424)
29. Bagheri-Yarmand R, Mazumdar A, Satin AA, Kumar R. LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system. Int J Cancer 2006; 118: 2703-2710. (Pubitemid 43673347)
30. Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000; 406: 532-535. (Pubitemid 30625739)
31. Vega FM, Ridley AJ. Rho GTPases in cancer cell biology. FEBS Lett 2008; 582: 2093-2101.
32. Micuda S, Rö sel D, Ryska A, Bra'bek J. ROCK inhibitors as emerging therapeutic candidates for sarcomas. Curr Cancer Drug Targets 2010; 10: 127-134.
33. Fackler OT, Grosse R. Cell motility through plasma membrane blebbing. J Cell Biol 2008; 181: 879-884. (Pubitemid 351846821)
34. Di Vizio D, Kim J, Hager MH, Morello M, Yang W, Lafargue CJ et al. Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res 2009; 69: 5601-5609.
35. Charras GT, Hu CK, Coughlin M, Mitchison TJ. Reassembly of contractile actin cortex in cell blebs. J Cell Biol 2006; 175: 477-490. (Pubitemid 44708071)